4th Quarter - Report — RK STRATEGIES, INC. for RECCE PHARMACEUTICALS LTD (2023)

Firm

RK STRATEGIES, INC.

Client

RECCE PHARMACEUTICALS LTD

Income

$20,000

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Pandemic All Hazards Preparedness Act, S.3678 Pasteur Act, H.R.3932

Foreign entity interest: Recce Pharmaceuticals Inc is principally located in Sydney, Australia

Lobbyist	Covered position, as disclosed
RYAN KANE	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 3678 (118th), H.R. 3932 (118th)

Defense DEF

Anti-Infectives Legislation National Defense Authorization Act of 2024, S.2226

Foreign entity interest: Recce Pharmaceuticals Inc is principally located in Sydney, Australia

Lobbyist	Covered position, as disclosed
RYAN KANE	—

Contacted: Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2226 (118th)

Veterans VET

Anti-Infectives Legislation

Foreign entity interest: Recce Pharmaceuticals Inc is principally located in Sydney, Australia

Lobbyist	Covered position, as disclosed
RYAN KANE	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

Entity	Country	Principal place of business	Ownership	Contribution declared
RECCE PHARMACEUTICALS INC	Australia	United States	100.0%	$20,000

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.